As sustainable development increasingly becomes a global consensus, Sino Biopharm, a leading innovation and R&D-driven pharmaceutical group in China, has always practiced the concept of sustainability and works hand-in-hand with all stakeholders for common progress. With its continuous and stable ESG practical performance, Sino Biopharm was included in the FTSE4Good Index Series for the first time in June of this year.

The FTSE4Good Index Series, founded in 2001, is the world's first index series to measure the performance of companies that meet globally recognized corporate responsibility standards. It aims to identify and recognize companies with outstanding performance in Environmental, Social, and Governance (ESG) practices. With its highly transparent index management and calculation criteria, the index has become a valuable reference for investment advisors, asset owners, fund managers, investment banks, stock exchanges, and brokers, helping them evaluate or create investment products that align with social responsibility values. To be eligible for inclusion in the FTSE4Good Index Series, companies must implement relevant measures across multiple corporate responsibility themes, including environmental management, climate change mitigation, anti-corruption, human rights protection, labor rights, and labor standards in the supply chain, and meet strict global criteria to become a constituent stock of the FTSE4Good Index Series.

In recent years, under the leadership of the Board of Directors, Sino Biopharm has continuously promoted the deep implementation of its "CARE" ESG strategy in the field of operational management. The Board of Directors continuously improves its performance in terms of professionalism, independence, and diversity, and leverages digital transformation to continuously enhance its decision-making capabilities. Building on this foundation, the Group has systematically advanced an ESG governance enhancement transformation represented by "carbon neutrality planning", "responsible supply chain construction", "human development", and "medical accessibility expansion". This has led to significant achievements, including the continuous satisfaction of clinical needs, a year-on-year decrease in carbon dioxide emission intensity, a year-on-year increase in employee satisfaction, and a joint improvement in the sustainability level of the industrial chain.

Sino Biopharm's first-time inclusion in the FTSE4GOOD Index Series represents the continuous and high recognition of its ESG practical performance by professional institutions in the international capital market. In the future, Sino Biopharm will adhere to its original mission of "Science for a healthier world", continuously integrate the ESG concept with the Group's development strategy, enhance risk management levels, promote stable business growth, and create long-term value for shareholders, patients, employees, and all sectors of society.